Drug Type Small molecule drug |
Synonyms SB 683698, SB-683698, TR 14035 |
Target |
Action antagonists |
Mechanism α4β1 antagonists(Integrin alpha-4/beta-1 antagonists), α4β7 antagonists(Integrin alpha-4/beta-7 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H21Cl2NO5 |
InChIKeyDRSJLVGDSNWQBI-SFHVURJKSA-N |
CAS Registry232271-19-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Asthma | Phase 2 | United States | - | |
Asthma | Phase 2 | Japan | - | - |
Asthma | Phase 2 | Europe | - | - |
Asthma | Phase 2 | - | - | |
Multiple Sclerosis | Phase 2 | - | - | |
Rheumatoid Arthritis | Phase 2 | United States | - | |
Rheumatoid Arthritis | Phase 2 | Japan | - | - |
Rheumatoid Arthritis | Phase 2 | Europe | - | - |
Rheumatoid Arthritis | Phase 2 | - | - | |
Irritable Bowel Syndrome | Phase 1 | United States | - |